JPS58189180A - イミダゾピリジン化合物およびその医薬への応用 - Google Patents
イミダゾピリジン化合物およびその医薬への応用Info
- Publication number
- JPS58189180A JPS58189180A JP58070849A JP7084983A JPS58189180A JP S58189180 A JPS58189180 A JP S58189180A JP 58070849 A JP58070849 A JP 58070849A JP 7084983 A JP7084983 A JP 7084983A JP S58189180 A JPS58189180 A JP S58189180A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- represented
- item
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Imidazopyridine compound Chemical class 0.000 title claims description 5
- 239000003814 drug Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 150000002825 nitriles Chemical class 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- YDHIMEXEGOCNHU-UHFFFAOYSA-N 2-pyridin-3-ylacetamide Chemical compound NC(=O)CC1=CC=CN=C1 YDHIMEXEGOCNHU-UHFFFAOYSA-N 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims description 3
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 claims description 3
- 150000003222 pyridines Chemical class 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000026680 Metabolic Brain disease Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 230000037007 arousal Effects 0.000 claims description 2
- 230000003542 behavioural effect Effects 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 4
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XZXYQEHISUMZAT-UHFFFAOYSA-N 2-[(2-hydroxy-5-methylphenyl)methyl]-4-methylphenol Chemical compound CC1=CC=C(O)C(CC=2C(=CC=C(C)C=2)O)=C1 XZXYQEHISUMZAT-UHFFFAOYSA-N 0.000 description 1
- OXSSYPPKLZCGID-UHFFFAOYSA-N 2-[2-(5-chlorothiophen-2-yl)-6-methylimidazo[1,2-a]pyridin-3-yl]acetonitrile Chemical compound N#CCC=1N2C=C(C)C=CC2=NC=1C1=CC=C(Cl)S1 OXSSYPPKLZCGID-UHFFFAOYSA-N 0.000 description 1
- VVKCFHFNEMHXMM-UHFFFAOYSA-N 2-[6-chloro-2-(5-chlorothiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]-n,n-dimethylacetamide Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(Cl)S1 VVKCFHFNEMHXMM-UHFFFAOYSA-N 0.000 description 1
- 150000003930 2-aminopyridines Chemical class 0.000 description 1
- BYKVUGZUYJUSKD-UHFFFAOYSA-N 2-bromo-1-pyridin-2-ylethanone;hydron;bromide Chemical compound [Br-].BrCC(=O)C1=CC=CC=[NH+]1 BYKVUGZUYJUSKD-UHFFFAOYSA-N 0.000 description 1
- NSJOHWXCJYNOSF-UHFFFAOYSA-N 2-imidazo[1,2-a]pyridin-3-ylacetamide Chemical compound C1=CC=CN2C(CC(=O)N)=CN=C21 NSJOHWXCJYNOSF-UHFFFAOYSA-N 0.000 description 1
- ZVBVKRNOISRONE-UHFFFAOYSA-N 2-imidazo[1,2-a]pyridin-3-ylacetic acid Chemical compound C1=CC=CN2C(CC(=O)O)=CN=C21 ZVBVKRNOISRONE-UHFFFAOYSA-N 0.000 description 1
- PJWDPOBWIWWXCP-UHFFFAOYSA-N 2-imidazo[1,2-a]pyridin-3-ylacetonitrile Chemical compound C1=CC=CN2C(CC#N)=CN=C21 PJWDPOBWIWWXCP-UHFFFAOYSA-N 0.000 description 1
- 206010059150 Cerebrosclerosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940107816 ammonium iodide Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- SAVROPQJUYSBDD-UHFFFAOYSA-N formyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CO SAVROPQJUYSBDD-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8206841 | 1982-04-21 | ||
| FR8206841A FR2525602A1 (fr) | 1982-04-21 | 1982-04-21 | Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58189180A true JPS58189180A (ja) | 1983-11-04 |
| JPH0412270B2 JPH0412270B2 (enExample) | 1992-03-04 |
Family
ID=9273216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58070849A Granted JPS58189180A (ja) | 1982-04-21 | 1983-04-20 | イミダゾピリジン化合物およびその医薬への応用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4492695A (enExample) |
| EP (1) | EP0092459B1 (enExample) |
| JP (1) | JPS58189180A (enExample) |
| AT (1) | ATE23860T1 (enExample) |
| AU (1) | AU553112B2 (enExample) |
| CA (1) | CA1254207A (enExample) |
| DE (1) | DE3367918D1 (enExample) |
| DK (1) | DK173783A (enExample) |
| ES (1) | ES8402298A1 (enExample) |
| FI (1) | FI73998C (enExample) |
| FR (1) | FR2525602A1 (enExample) |
| GR (1) | GR78577B (enExample) |
| HU (1) | HU189648B (enExample) |
| IE (1) | IE54923B1 (enExample) |
| IL (1) | IL68443A0 (enExample) |
| NO (1) | NO156048C (enExample) |
| NZ (1) | NZ203955A (enExample) |
| PT (1) | PT76574B (enExample) |
| ZA (1) | ZA832787B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3406329A1 (de) * | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
| FR2606410B1 (fr) * | 1986-11-07 | 1989-02-24 | Synthelabo | Imidazopyridines, leur preparation et leur application en therapeutique |
| US5364849A (en) * | 1989-04-22 | 1994-11-15 | John Wyeth & Brother, Limited | 1-[3 or 4-[1-[4-piperazinyl]]-2 arylpropionyl or butryl]-heterocyclic derivatives |
| JP2944048B2 (ja) * | 1993-07-06 | 1999-08-30 | フアイザー・インコーポレイテツド | 二環式テトラヒドロピラゾロピリジン |
| WO1998025926A1 (en) * | 1996-12-11 | 1998-06-18 | Takeda Chemical Industries, Ltd. | Imidazopyridine derivatives and their production |
| AUPP278498A0 (en) | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
| WO2001009131A1 (en) * | 1999-07-30 | 2001-02-08 | Zenyaku Kogyo Kabushiki Kaisha | Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient |
| IT1318624B1 (it) * | 2000-07-14 | 2003-08-27 | Dinamite Dipharma S P A In For | Processo per la preparazione di 2-fenil-imidazo (1,2-a)piridin-3-acetammidi. |
| SE0003186D0 (sv) * | 2000-09-07 | 2000-09-07 | Astrazeneca Ab | New process |
| US6596731B2 (en) | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
| US8555875B2 (en) | 2008-12-23 | 2013-10-15 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| US8927545B2 (en) * | 2009-03-30 | 2015-01-06 | Duke University | Inhibiting Eph B-3 kinase |
| CN106866667B (zh) | 2009-11-05 | 2019-11-15 | 圣母大学 | 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法 |
| CN103360387B (zh) * | 2012-03-28 | 2016-12-14 | 江苏豪森药业集团有限公司 | 一种制备化合物唑吡坦的方法 |
| KR20180053386A (ko) | 2015-09-17 | 2018-05-21 | 마빈 제이. 밀러 | 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물 |
| EP3468545A4 (en) | 2016-06-08 | 2020-07-22 | President and Fellows of Harvard College | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME AND FRAGILE X SYNDROME |
| CN107163039A (zh) * | 2017-05-11 | 2017-09-15 | 浙江工业大学 | 一种6‑甲基‑2‑对甲苯基咪唑并[1,2‑a]吡啶‑3‑甲醛的制备方法 |
| EP3797097A4 (en) | 2018-05-22 | 2022-03-09 | President and Fellows of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| US11434244B2 (en) | 2018-05-29 | 2022-09-06 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| EP3946390A4 (en) | 2019-03-25 | 2022-12-21 | President and Fellows of Harvard College | COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1076089A (en) * | 1965-11-09 | 1967-07-19 | Selvi & C Lab Bioterapico | New derivatives of imidazo [1,2-a]-pyridine and a process for the manufacture thereof |
| FR2492382A1 (fr) * | 1980-10-22 | 1982-04-23 | Synthelabo | Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique |
-
1982
- 1982-04-21 FR FR8206841A patent/FR2525602A1/fr active Granted
-
1983
- 1983-04-07 DE DE8383400706T patent/DE3367918D1/de not_active Expired
- 1983-04-07 EP EP83400706A patent/EP0092459B1/fr not_active Expired
- 1983-04-07 AT AT83400706T patent/ATE23860T1/de not_active IP Right Cessation
- 1983-04-13 US US06/484,611 patent/US4492695A/en not_active Expired - Fee Related
- 1983-04-20 IL IL68443A patent/IL68443A0/xx not_active IP Right Cessation
- 1983-04-20 NZ NZ203955A patent/NZ203955A/en unknown
- 1983-04-20 PT PT76574A patent/PT76574B/pt not_active IP Right Cessation
- 1983-04-20 AU AU13700/83A patent/AU553112B2/en not_active Ceased
- 1983-04-20 CA CA000426243A patent/CA1254207A/en not_active Expired
- 1983-04-20 NO NO831390A patent/NO156048C/no unknown
- 1983-04-20 DK DK173783A patent/DK173783A/da active IP Right Grant
- 1983-04-20 HU HU831381A patent/HU189648B/hu not_active IP Right Cessation
- 1983-04-20 JP JP58070849A patent/JPS58189180A/ja active Granted
- 1983-04-20 GR GR71139A patent/GR78577B/el unknown
- 1983-04-20 ES ES521651A patent/ES8402298A1/es not_active Expired
- 1983-04-20 ZA ZA832787A patent/ZA832787B/xx unknown
- 1983-04-20 FI FI831349A patent/FI73998C/fi not_active IP Right Cessation
- 1983-04-20 IE IE896/83A patent/IE54923B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0412270B2 (enExample) | 1992-03-04 |
| DK173783A (da) | 1983-10-22 |
| PT76574A (fr) | 1983-05-01 |
| EP0092459A2 (fr) | 1983-10-26 |
| ATE23860T1 (de) | 1986-12-15 |
| ES521651A0 (es) | 1984-01-16 |
| IL68443A0 (en) | 1983-07-31 |
| FI831349A0 (fi) | 1983-04-20 |
| EP0092459A3 (en) | 1984-02-01 |
| AU553112B2 (en) | 1986-07-03 |
| FR2525602B1 (enExample) | 1984-06-22 |
| NO831390L (no) | 1983-10-24 |
| NZ203955A (en) | 1985-11-08 |
| ES8402298A1 (es) | 1984-01-16 |
| FR2525602A1 (fr) | 1983-10-28 |
| US4492695A (en) | 1985-01-08 |
| NO156048B (no) | 1987-04-06 |
| HU189648B (en) | 1986-07-28 |
| DE3367918D1 (en) | 1987-01-15 |
| GR78577B (enExample) | 1984-09-27 |
| CA1254207A (en) | 1989-05-16 |
| FI831349L (fi) | 1983-10-22 |
| NO156048C (no) | 1987-07-15 |
| AU1370083A (en) | 1983-10-27 |
| FI73998B (fi) | 1987-08-31 |
| PT76574B (fr) | 1986-02-27 |
| EP0092459B1 (fr) | 1986-11-26 |
| IE830896L (en) | 1983-10-21 |
| ZA832787B (en) | 1983-12-28 |
| FI73998C (fi) | 1987-12-10 |
| IE54923B1 (en) | 1990-03-28 |
| DK173783D0 (da) | 1983-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58189180A (ja) | イミダゾピリジン化合物およびその医薬への応用 | |
| JP3333523B2 (ja) | オキサジアゾール、それらの調製方法及び医薬組成物としてのそれらの使用 | |
| JP4295505B2 (ja) | 新規なラクタム置換ピラゾロピリジン誘導体 | |
| JPS6147485A (ja) | ３‐アシルアミノメチルイミダゾ［１，２‐ａ］ピリジン誘導体 | |
| US4721711A (en) | Pyridazine derivatives active on the central nervous system, and medicaments in which they are present | |
| BG61367B2 (bg) | Циклоалкилтриазоли | |
| JPH01246265A (ja) | ４‐ピリドン‐３‐カルボン酸誘導体 | |
| JPS59501409A (ja) | ピリドン化合物 | |
| JPH0313235B2 (enExample) | ||
| JPS58189179A (ja) | イミダゾピリジン誘導体 | |
| WO2012152630A1 (de) | Substituierte imidazopyridazine und ihre verwendung | |
| EP0089028B1 (de) | Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung | |
| JPS59137469A (ja) | 複素環式化合物，その製法およびそれらを含有する中枢神経系薬物 | |
| US3828057A (en) | Amino derivatives of pyrazolopyridine ketones | |
| US4524149A (en) | 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their cardiotonic use | |
| JPS5995287A (ja) | ２−（ピリジニルまたはヒドロキシフエニル）８−置換ピリド〔２，３−ｄ〕ピリミジン−５（８Ｈ）−オン類、その製造方法およびそれを含む医薬組成物 | |
| USRE30024E (en) | 4-Amino (or hydrazino)-2-(pyridinyl)pyrimidines | |
| JPS59206356A (ja) | 新規５−アシル−２−（１ｈ）−ピリジノン類 | |
| JP2014532656A (ja) | 炎症および免疫関連用途のための化合物 | |
| JP2010500330A (ja) | Ｇａｂａａ受容体に対して親和性を有する１ｈ−キノリン−４−オン化合物、方法、使用及び組成物 | |
| US3378564A (en) | Certain pyridyl tetrazole derivatives | |
| US4032523A (en) | 4-amino (or halo or hydroxy or hydrazino)-2-(pyridinyl)pyrimidines | |
| CN115260107B (zh) | 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用 | |
| US4418062A (en) | Amino derivatives of chloro nitro amino pyrazines useful as adjuncts to radiation therapy | |
| JPH0114236B2 (enExample) |